What Sebacil 7.5% Treats: Main Uses and Benefits

Sebacil 7.5% is commonly used in veterinary medicine for the control of ectoparasites, targeting conditions that lead to physical discomfort in livestock. The active component is applied in addressing conditions involving mites, lice, and ticks, including various forms of mange and scabies.

This therapeutic domain is relevant for easing symptoms related to inflammatory or irritative states where groups of symptoms may become intense or disruptive. The primary benefit is to support the elimination of the causative pests, which may assist with easing severe itching and helps improve overall skin integrity and comfort.

“It is utilized to maintain low parasitic loads and support the prevention of sudden symptom escalation, thereby offering symptomatic relief.”

The medication is commonly used to help with managing significant ectoparasite burdens, being relevant in specific prophylactic clinical scenarios and during acute symptom-driven episodes. It provides support that helps ease the overall symptom burden on the animals, assisting with maintaining functional stability and comfort.

---

Quick Fact: Relief for Parasite-Driven Irritation

Sebacil 7.5% is applied in addressing conditions characterized by heightened symptoms of external irritation, such as skin lesions and intense itching caused by arthropod pests. Its use contributes to supporting the health status of the production system by integrating into biosecurity and parasite control protocols.

Population Eligibility for Sebacil 7.5%

The use of Sebacil 7.5% (Phoxim) is restricted to specific animal populations and health statuses as defined in regulatory documentation. The product is officially authorized for use only in pigs (porcins) for the treatment of sarcoptic mange and louse infestations. Use in any other species is not established.

---

Absolute Contraindications

Sebacil 7.5% is formally contraindicated and must not be administered to animals in certain physiological states:

• Animals that are sick or very stressed.
• Convalescent animals or those in a reconvulsive period.
• Animals with a known hypersensitivity to phoxim or any organophosphorus compounds.

---

Conditional Use and Restrictions

Eligibility is conditional for certain populations, requiring particular care during administration. This caution applies to animals with pre-existing conditions such as heart failure, bronchospasm, susceptibility to convulsions, liver (hepatic) disease, or kidney (renal) disease.

Regarding co-treatment, the medicine is prohibited for use concurrently with other cholinesterase inhibitors. It is also restricted from being administered 10 days before or 10 days after the use of phenothiazine or mymiorelaxants. Use is documented as permitted during all stages of gestation in sows.

Interactions with other medicines and products — official regulatory information for Sebacil 7.5%

The interaction profile for Sebacil 7.5%, an ectoparasiticide containing the active ingredient Phoxim, is governed by the findings presented in government-approved regulatory documentation. A review of the official labeling indicates that there are no known interactions with other medicinal products or substances. This status establishes the high-level classification for all potential interaction domains.

---

Interaction Scope

Entity	Officially Documented Status
Medicinal Product Interactions	None known or documented.
Mechanistic Basis of Interactions	No specific pharmacokinetic or pharmacodynamic mechanisms are documented.
Timing-based Interaction Rules	No mandatory separation rules are documented.

---

Interaction Classifications (High-Level)

Classification	Officially Documented Status
Contraindicated Combinations	None listed in regulatory documents.
Exposure-Modifying Substances	None documented to alter drug levels.
Food, Alcohol, Herbal Products	No specific interactions are documented.

---

Resulting Interaction Structure

Official interaction statements:

• The official regulatory documentation explicitly states there are no known interactions with other medicinal products.
• No specific contraindicated combinations are listed in the regulatory interaction section.
• The labeling does not document any interactions that modify exposure or require timing separation.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents defining the product's interaction structure confirm that no interactions are known with other medicinal products or substances. This official finding means that the product labeling contains no formal requirements for dose spacing, no listed contraindicated drug pairings, and no documented pharmacokinetic or pharmacodynamic interaction constraints with other substances.

How Sebacil 7.5% Works: Mechanism of Action

The mechanism of action for Sebacil 7.5% (Phoxim) is centered on altering key enzymatic activity within the nervous system of targeted ectoparasites (mites, lice, etc.), which is characteristic of organophosphate compounds.

---

Neurotransmitter Overload via Enzyme Inhibition

The primary biological action of Phoxim is the irreversible inhibition of acetylcholinesterase (AChE). This mechanism prevents the hydrolysis of the neurotransmitter acetylcholine (ACh) at the synaptic cleft, resulting in a sustained and excessive accumulation of ACh. The resulting physiological effect is a severe, continuous overstimulation of the parasite's nerve and muscle cells, which results in sustained neuromuscular hyperexcitation and subsequent functional cessation.

---

Disruption of Cholinergic Signal Termination

This mechanistic area focuses on the functional consequence of AChE inhibition within the cholinergic system. By blocking the enzyme responsible for rapidly clearing the nerve signal, the drug engages mechanisms that completely suppress the natural termination of nerve impulses. This leads to a state of hyperexcitation followed by functional exhaustion of the nervous system. The sequence of events culminates in a state of sustained neuromuscular overactivity and subsequent physiological failure within the ectoparasite.

Official Administration Instructions for Sebacil 7.5% Pour-on Solution

Sebacil 7.5% (Phoxim 75 mg/mL) is a veterinary medicinal product for topical use only, applied as a pour-on solution for pigs. Strict adherence to the official dosing and administration schedule is required to ensure proper use and to respect the mandatory withdrawal period.

---

Dosing and Administration

Administration Detail	Official Requirement
Route of Administration	Topical Pour-on use.
Dose Calculation	0.4 mL of solution per 1 kg body weight (BW) of the pig. This delivers 30 mg Phoxim/kg BW.
Preparation	The solution is ready-to-use and must not be diluted.

---

Procedural Steps and Schedule

1. Dose Measurement: Accurately determine the pig's body weight to calculate the exact volume of Sebacil 7.5% needed.
2. Application Site: Apply the measured volume of the solution as a pour-on along the back of the animal, running from the ear to the base of the tail.
3. Special Application: For severe infestations in the ears (earworms), 1-2 mL of the calculated dose should be poured directly into each ear.
4. Frequency: One treatment is typically sufficient. For severe cases, such as mange, the treatment must be repeated after 14 days.

---

Use-Context Constraints

• Withdrawal Period: A mandatory waiting period of 17 days must be observed between the final administration and the slaughter of the animal for human consumption of meat and offal.
• Other Medications: Do not administer other cholinesterase inhibitors or certain muscle relaxants (e.g., phenothiazine, myorelaxants) for 10 days before and 10 days after Sebacil 7.5% administration.

Summary of Research Findings

Overview of Clinical Research

The compound, Phoxim, is an organophosphate insecticide. Research studies on Sebacil 7.5% have primarily focused on its application in veterinary medicine for the treatment of ectoparasites in livestock, such as scabies mites and lice in pigs. No clinical studies supporting the use of this specific compound formulation for human chronic inflammatory conditions (CIC) have been identified. For human health information regarding inflammation, individuals should refer to research on approved pharmacological agents.

Key Study Observations (Veterinary Context)

The available data on Sebacil 7.5% comes primarily from veterinary trials and residue studies, which investigated the compound's effect on target parasites and its metabolism in animals.

Parasite Control

Studies evaluated the use of the 7.5% pour-on solution for controlling external parasites, specifically Sarcoptes scabiei var. suis (scabies) and Haematopinus suis (lice) in pigs. Data collection protocols focused on measuring the reduction in visible parasite counts following application.

Pharmacokinetics and Safety Monitoring

Research protocols included the monitoring of phoxim's absorption and excretion rates in animal models to determine residue levels. These studies established withdrawal periods—the time required before animals can be cleared for consumption—to ensure safety standards were met. Long-term studies in non-target species, such as dogs, have been utilized to establish acceptable daily intake (ADI) levels by governmental and international food safety committees, focusing on effects on liver function and acetylcholinesterase activity.

Common questions about Sebacil 7.5% (FAQ)

Q: What specific skin conditions is Sebacil 7.5% officially approved to treat?

According to official regulatory documents, Sebacil 7.5% is approved for the treatment of ectoparasites (external parasites) in animals, such as lice, ticks, flies, and itch mites (Psoroptes, Sarcoptes, Chorioptes). This ectoparasiticide is indicated for the treatment of conditions caused by these infestations, including forms of mange. The approved use is strictly defined by the regulatory body.

Q: Is Sebacil 7.5% considered an antibiotic, antiseptic, or something else?

Official product information classifies Sebacil 7.5% as an ectoparasiticide, meaning it is specifically designed to kill parasites on the body surface. Its active ingredient, Phoxim, belongs to a chemical class known as organophosphates and works by affecting the nervous system of the target pests.

Q: Is there an age limit for who can use Sebacil 7.5% according to regulatory documents?

Regulatory documents do not specify an age limit for use. Instead, the official administration instructions require dosing to be based on the animal’s exact body weight (0.4 mL per 1 kg BW). This weight-based measurement serves as the criterion for administration regardless of the animal's age.

Q: Are there any specific pre-existing health conditions that prevent the use of Sebacil 7.5%?

Yes, regulatory warnings indicate the product should not be used in animals that are sick, exhausted, or under severe stress. Specific caution is noted for animals with pre-existing issues like heart failure, bronchospasm, or liver or kidney disease. The labeling also states it should not be administered near the same time as certain other medications, such as cholinesterase inhibitors.

Q: What is the difference between a cream and a gel formulation of Sebacil 7.5%?

Sebacil 7.5% is formulated and supplied as a ready-to-use pour-on solution for topical application; it is not available or studied as a cream or a gel formulation. The pour-on solution is designed for administration along the animal's back.

Q: Does Sebacil 7.5% get absorbed into the bloodstream after topical application?

Toxicology reports indicate that the active ingredient, Phoxim, is known to be absorbed after application to the animal's skin. The level of absorption results in residues in animal tissues, which is why a mandatory withdrawal period is required before slaughter for human consumption.

Q: Is temporary redness or irritation a common side effect of Sebacil 7.5%?

Official product labeling documents that local cases of itching and allergic reactions around the application site have been observed in some treated animals.

Q: Are there any known severe or life-threatening allergic reactions associated with Sebacil 7.5%?

The product labeling reports documented cases of local allergic reactions. The regulatory summary information does not explicitly detail the severity or life-threatening status of these reactions, but any suspected allergic response should be noted.

Q: What should be done if Sebacil 7.5% accidentally gets into the eyes or mouth?

Safety precautions state that the drug should not contact the mucous membranes or eyes of the animal. If accidental contact with the eyes occurs, official safety precautions state the eyes must be immediately rinsed thoroughly with plenty of water.

Q: Is Sebacil 7.5% contraindicated for use during pregnancy or while trying to conceive?

Official regulatory warnings advise that the drug is contraindicated for use during the lactation period in females whose milk is intended for human consumption. Specific contraindications related to pregnancy are not summarized in the general product information.

Q: What does the official labeling say about using Sebacil 7.5% while breastfeeding?

The product should not be used for females during lactation whose milk is intended for human food consumption. This is an explicit constraint found in the official safety and contraindication documents.

Q: Can Sebacil 7.5% be used on broken or severely irritated skin?

Regulatory labeling explicitly states not to use the product on animals with skin damages. The product's instructions specify that application is for intact skin only.

Q: What warnings are listed for patients who have kidney or liver issues?

Official product information states that particular care should be taken when the product is administered to animals with pre-existing liver or kidney disease.

Q: What type of clinical studies (e.g., Phase 3 trials) support the use of Sebacil 7.5%?

Toxicology reports used to establish safety thresholds reference supporting studies, such as chronic exposure assessments. For example, reports cite findings from a 2-year chronic study in dogs which helped determine the No-Observed-Effect Level (NOEL) for the active ingredient Phoxim.

Q: Are there summary details available about the demographics of the clinical trial participants?

Toxicology reports contain summary details about the test subjects used to establish safety standards, referencing the animal species and the distribution used. For example, reports indicate the use of specific breeds of animals in the chronic toxicity studies, such as Beagles.

Q: Does the research evidence for Sebacil 7.5% include long-term safety data?

Long-term safety is assessed through toxicology data, which includes findings from chronic studies. Regulatory safety assessments for the active ingredient Phoxim are supported by results from a 2-year chronic study in dogs (104 weeks), which is used to assess long-term safety thresholds.

Q: What is the correct way to dispose of leftover or unused Sebacil 7.5% medication?

To safely dispose of unused working solution, regulatory guidelines state that it must be deactivated (for instance, with slaked calx) before being safely mixed with fertilizer or manure. Empty containers must also be utilized in accordance with local environmental legislation.

Q: Does Sebacil 7.5% expire, and what are the risks of using an expired product?

Official product stability information states that the manufactured product has an expiration date of 2.5 years. The prepared working solution itself is only suitable for 2 days after mixing.

Q: What is the typical shelf life of Sebacil 7.5% after the tube has been opened?

Since Sebacil 7.5% is supplied as a pour-on solution and often prepared for immediate use, the most relevant shelf-life constraint is for the prepared working solution, which is only suitable for 2 days.

Q: Is Sebacil 7.5% known to cause antibiotic resistance or cross-resistance?

Sebacil 7.5% is classified as an organophosphate insecticide that inhibits acetylcholinesterase, a mechanism of action distinct from antibiotics. Resistance involves changes in the parasite's detoxification enzymes rather than typical antibiotic resistance pathways.

How to Store and Dispose of Sebacil 7.5%?

The storage and disposal of Sebacil 7.5% (Phoxim 7.5% solution) must adhere strictly to the requirements defined in official veterinary medicinal product labeling to ensure stability and environmental safety.

Required Storage Conditions

The product must be stored below 25°C and must not be frozen, as freezing can compromise the solution.

Condition	Requirement
Temperature	Store below 25 C
Container	Keep in the original container and tightly closed
Protection	Protect from light and moisture (keep dry)
Safety	Keep out of the sight and reach of children

Disposal Instructions

Official regulations require that unused product or waste material be disposed of according to local requirements for veterinary pharmaceuticals. Due to the toxicity of the active ingredient (Phoxim) to aquatic organisms, the product must not be disposed of into watercourses, drainage systems, or the ground.